Rolipram versus nortriptyline in gerontopsychiatric inpatients with major depression
To define the therapeutic profile of the new putative antidepressant rolipram, a double-blind (double-dummy) study with 0.5 mg rolipram versus 25 mg nortriptyline three times daily was conducted in hospitalized gerontopsychiatric inpatients with major depression. During both therapies, improvement w...
Gespeichert in:
| Veröffentlicht in: | Nordic journal of psychiatry 1992, Vol.46 (6), p.407-411 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 411 |
|---|---|
| container_issue | 6 |
| container_start_page | 407 |
| container_title | Nordic journal of psychiatry |
| container_volume | 46 |
| creator | Behnke, K. Mejer-Nielsen, B. Korner, A. Arup, P. Geisler, A. Sastre-Y-Hernández, M. Bischoff, R. Schratzer, M. Voet, B. |
| description | To define the therapeutic profile of the new putative antidepressant rolipram, a double-blind (double-dummy) study with 0.5 mg rolipram versus 25 mg nortriptyline three times daily was conducted in hospitalized gerontopsychiatric inpatients with major depression. During both therapies, improvement was achieved compared with base line. However, the rate of recovery in patients treated with 3×25 mg nortriptyline was significantly greater than in those treated with 3×0.5 mg rolipram. Overall, rolipram was better tolerated than nortriptyline and produced fewer adverse effects that could be attributed to cholinergic blocking. We conclude that 3×0.5 mg rolipram presumably is too low a dosage for the treatment of major depression in gerontopsychiatric inpatients. |
| doi_str_mv | 10.3109/08039489209167898 |
| format | Article |
| fullrecord | <record><control><sourceid>informahealthcare_cross</sourceid><recordid>TN_cdi_crossref_primary_10_3109_08039489209167898</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_3109_08039489209167898</sourcerecordid><originalsourceid>FETCH-LOGICAL-c263t-51a6c2cb29971ab827438b341258e751a014d60aa636e244c0ebdf29dbe04463</originalsourceid><addsrcrecordid>eNp9kNtKxDAQhoMouK4-gHd9gWpOTRP0RhZPsCDI3pc0TW2WNimTrEvf3i7rjYheDcw33wzzI3RN8A0jWN1iiZniUlGsiCilkidoQQpMc17S4hQtDjyfB-Q5uohxizFmjKoF2ryH3o2gh-zTQtzFzAdI4MY09c7bzPnsw0LwKYxxMp3TMzNzd9TJWZ9itnepywa9DZA1dgQbowv-Ep21uo_26rsu0ebpcbN6yddvz6-rh3VuqGApL4gWhpqaKlUSXUtaciZrxgktpC1niglvBNZaMGEp5wbbummpamqLORdsichxrYEQI9i2GsENGqaK4OqQSvUrldm5PzrOtwEGvQ_QN1XSUx-gBe2Niwf1b_3uh95Z3afOaLDVNuzAz9_-c_wLAUh8kw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Rolipram versus nortriptyline in gerontopsychiatric inpatients with major depression</title><source>Taylor & Francis:Master (3349 titles)</source><source>Taylor & Francis Medical Library - CRKN</source><creator>Behnke, K. ; Mejer-Nielsen, B. ; Korner, A. ; Arup, P. ; Geisler, A. ; Sastre-Y-Hernández, M. ; Bischoff, R. ; Schratzer, M. ; Voet, B.</creator><creatorcontrib>Behnke, K. ; Mejer-Nielsen, B. ; Korner, A. ; Arup, P. ; Geisler, A. ; Sastre-Y-Hernández, M. ; Bischoff, R. ; Schratzer, M. ; Voet, B.</creatorcontrib><description>To define the therapeutic profile of the new putative antidepressant rolipram, a double-blind (double-dummy) study with 0.5 mg rolipram versus 25 mg nortriptyline three times daily was conducted in hospitalized gerontopsychiatric inpatients with major depression. During both therapies, improvement was achieved compared with base line. However, the rate of recovery in patients treated with 3×25 mg nortriptyline was significantly greater than in those treated with 3×0.5 mg rolipram. Overall, rolipram was better tolerated than nortriptyline and produced fewer adverse effects that could be attributed to cholinergic blocking. We conclude that 3×0.5 mg rolipram presumably is too low a dosage for the treatment of major depression in gerontopsychiatric inpatients.</description><identifier>ISSN: 0803-9488</identifier><identifier>EISSN: 1502-4725</identifier><identifier>DOI: 10.3109/08039489209167898</identifier><language>eng</language><publisher>Informa UK Ltd</publisher><subject>Antidepressants ; Gerontopsychiatry ; Major depression ; Phosphodiesterase inhibitors ; Rolipram</subject><ispartof>Nordic journal of psychiatry, 1992, Vol.46 (6), p.407-411</ispartof><rights>1992 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 1992</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c263t-51a6c2cb29971ab827438b341258e751a014d60aa636e244c0ebdf29dbe04463</citedby><cites>FETCH-LOGICAL-c263t-51a6c2cb29971ab827438b341258e751a014d60aa636e244c0ebdf29dbe04463</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.3109/08039489209167898$$EPDF$$P50$$Ginformahealthcare$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.3109/08039489209167898$$EHTML$$P50$$Ginformahealthcare$$H</linktohtml><link.rule.ids>314,776,780,4009,27902,27903,27904,59623,59729,60412,60518,61197,61232,61378,61413</link.rule.ids></links><search><creatorcontrib>Behnke, K.</creatorcontrib><creatorcontrib>Mejer-Nielsen, B.</creatorcontrib><creatorcontrib>Korner, A.</creatorcontrib><creatorcontrib>Arup, P.</creatorcontrib><creatorcontrib>Geisler, A.</creatorcontrib><creatorcontrib>Sastre-Y-Hernández, M.</creatorcontrib><creatorcontrib>Bischoff, R.</creatorcontrib><creatorcontrib>Schratzer, M.</creatorcontrib><creatorcontrib>Voet, B.</creatorcontrib><title>Rolipram versus nortriptyline in gerontopsychiatric inpatients with major depression</title><title>Nordic journal of psychiatry</title><description>To define the therapeutic profile of the new putative antidepressant rolipram, a double-blind (double-dummy) study with 0.5 mg rolipram versus 25 mg nortriptyline three times daily was conducted in hospitalized gerontopsychiatric inpatients with major depression. During both therapies, improvement was achieved compared with base line. However, the rate of recovery in patients treated with 3×25 mg nortriptyline was significantly greater than in those treated with 3×0.5 mg rolipram. Overall, rolipram was better tolerated than nortriptyline and produced fewer adverse effects that could be attributed to cholinergic blocking. We conclude that 3×0.5 mg rolipram presumably is too low a dosage for the treatment of major depression in gerontopsychiatric inpatients.</description><subject>Antidepressants</subject><subject>Gerontopsychiatry</subject><subject>Major depression</subject><subject>Phosphodiesterase inhibitors</subject><subject>Rolipram</subject><issn>0803-9488</issn><issn>1502-4725</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><recordid>eNp9kNtKxDAQhoMouK4-gHd9gWpOTRP0RhZPsCDI3pc0TW2WNimTrEvf3i7rjYheDcw33wzzI3RN8A0jWN1iiZniUlGsiCilkidoQQpMc17S4hQtDjyfB-Q5uohxizFmjKoF2ryH3o2gh-zTQtzFzAdI4MY09c7bzPnsw0LwKYxxMp3TMzNzd9TJWZ9itnepywa9DZA1dgQbowv-Ep21uo_26rsu0ebpcbN6yddvz6-rh3VuqGApL4gWhpqaKlUSXUtaciZrxgktpC1niglvBNZaMGEp5wbbummpamqLORdsichxrYEQI9i2GsENGqaK4OqQSvUrldm5PzrOtwEGvQ_QN1XSUx-gBe2Niwf1b_3uh95Z3afOaLDVNuzAz9_-c_wLAUh8kw</recordid><startdate>1992</startdate><enddate>1992</enddate><creator>Behnke, K.</creator><creator>Mejer-Nielsen, B.</creator><creator>Korner, A.</creator><creator>Arup, P.</creator><creator>Geisler, A.</creator><creator>Sastre-Y-Hernández, M.</creator><creator>Bischoff, R.</creator><creator>Schratzer, M.</creator><creator>Voet, B.</creator><general>Informa UK Ltd</general><general>Taylor & Francis</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>1992</creationdate><title>Rolipram versus nortriptyline in gerontopsychiatric inpatients with major depression</title><author>Behnke, K. ; Mejer-Nielsen, B. ; Korner, A. ; Arup, P. ; Geisler, A. ; Sastre-Y-Hernández, M. ; Bischoff, R. ; Schratzer, M. ; Voet, B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c263t-51a6c2cb29971ab827438b341258e751a014d60aa636e244c0ebdf29dbe04463</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>Antidepressants</topic><topic>Gerontopsychiatry</topic><topic>Major depression</topic><topic>Phosphodiesterase inhibitors</topic><topic>Rolipram</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Behnke, K.</creatorcontrib><creatorcontrib>Mejer-Nielsen, B.</creatorcontrib><creatorcontrib>Korner, A.</creatorcontrib><creatorcontrib>Arup, P.</creatorcontrib><creatorcontrib>Geisler, A.</creatorcontrib><creatorcontrib>Sastre-Y-Hernández, M.</creatorcontrib><creatorcontrib>Bischoff, R.</creatorcontrib><creatorcontrib>Schratzer, M.</creatorcontrib><creatorcontrib>Voet, B.</creatorcontrib><collection>CrossRef</collection><jtitle>Nordic journal of psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Behnke, K.</au><au>Mejer-Nielsen, B.</au><au>Korner, A.</au><au>Arup, P.</au><au>Geisler, A.</au><au>Sastre-Y-Hernández, M.</au><au>Bischoff, R.</au><au>Schratzer, M.</au><au>Voet, B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Rolipram versus nortriptyline in gerontopsychiatric inpatients with major depression</atitle><jtitle>Nordic journal of psychiatry</jtitle><date>1992</date><risdate>1992</risdate><volume>46</volume><issue>6</issue><spage>407</spage><epage>411</epage><pages>407-411</pages><issn>0803-9488</issn><eissn>1502-4725</eissn><abstract>To define the therapeutic profile of the new putative antidepressant rolipram, a double-blind (double-dummy) study with 0.5 mg rolipram versus 25 mg nortriptyline three times daily was conducted in hospitalized gerontopsychiatric inpatients with major depression. During both therapies, improvement was achieved compared with base line. However, the rate of recovery in patients treated with 3×25 mg nortriptyline was significantly greater than in those treated with 3×0.5 mg rolipram. Overall, rolipram was better tolerated than nortriptyline and produced fewer adverse effects that could be attributed to cholinergic blocking. We conclude that 3×0.5 mg rolipram presumably is too low a dosage for the treatment of major depression in gerontopsychiatric inpatients.</abstract><pub>Informa UK Ltd</pub><doi>10.3109/08039489209167898</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0803-9488 |
| ispartof | Nordic journal of psychiatry, 1992, Vol.46 (6), p.407-411 |
| issn | 0803-9488 1502-4725 |
| language | eng |
| recordid | cdi_crossref_primary_10_3109_08039489209167898 |
| source | Taylor & Francis:Master (3349 titles); Taylor & Francis Medical Library - CRKN |
| subjects | Antidepressants Gerontopsychiatry Major depression Phosphodiesterase inhibitors Rolipram |
| title | Rolipram versus nortriptyline in gerontopsychiatric inpatients with major depression |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T19%3A17%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-informahealthcare_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Rolipram%20versus%20nortriptyline%20in%20gerontopsychiatric%20inpatients%20with%20major%20depression&rft.jtitle=Nordic%20journal%20of%20psychiatry&rft.au=Behnke,%20K.&rft.date=1992&rft.volume=46&rft.issue=6&rft.spage=407&rft.epage=411&rft.pages=407-411&rft.issn=0803-9488&rft.eissn=1502-4725&rft_id=info:doi/10.3109/08039489209167898&rft_dat=%3Cinformahealthcare_cross%3E10_3109_08039489209167898%3C/informahealthcare_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |